Cladribine vs placebo for non-active progressive multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether cladribine (vs an inactive placebo pill) can slow disability worsening in people with a non-active, progressive form of multiple sclerosis. It may help by reducing the immune activity that can drive ongoing nerve damage, even without recent relapses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to sign informed consent
- You have non-active secondary progressive or relapse-onset secondary progressive multiple sclerosis, not relapsing-remitting or primary progressive
- Your disability has been getting worse over the past 24 months, and you have no relapses in the last 12 months
- Your age is 30 to 65, and you’ve had MS for at least 10 years
- Your disability score (EDSS) is between 3.5 and 7.5
- You can follow strict birth-control rules (and avoid pregnancy) for up to 6 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
This Phase 2 trial studies whether a vitamin-like supplement called nicotinamide riboside can slow or improve disability in progressive multiple sclerosis. It may help people whose symptoms have been steadily getting worse over the last 2 years.
This study tests an experimental oral drug, PRO-1562, in two parts: first in healthy volunteers to check safety, then in people with relapsing multiple sclerosis to see if it can reduce disease activity. It may offer a new, convenient treatment option.
This trial tests a new treatment using a patient's own immune cells, modified with vitamin D3, to try to calm the immune system and slow the progression of multiple sclerosis (MS) without causing major side effects. It is for people with progressive MS who have not had recent relapses.
This trial tests whether a simple, non-invasive treatment called remote ischemic conditioning — using brief cycles of a blood pressure cuff on your arm — can improve walking and slow disability in people with primary progressive MS. It targets people with moderate disability who have trouble walking.
This Phase 2 study tests whether corticosteroid medicine can reduce inflammation at the edge of active multiple sclerosis (MS) plaques seen on MRI. It may help calm “hot” areas in the brain where MS activity is happening.
Hear when a new Multiple Sclerosis, Secondary Progressive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.